Buy Hair Growth Raw Powder Ru58841 Peptide Minoxidil

RU58841, also known as ‌1-(4-fluoronophenyl)-2,5-dimethyl-1H-imidazol-4-carboxylic acid ethyl ester‌ or more fully as ‌ethyl 1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazole-4-carboxylate‌, is a non-steroidal anti-androgen.

It was researched in the 1990s for the potential treatment of androgenetic alopecia (male pattern baldness) and acne. RU58841 acts as a selective androgen receptor modulator by blocking androgen receptors in specific tissues, thereby inhibiting the effects of androgens like dihydrotestosterone (DHT) without significantly affecting systemic hormone levels.

In terms of its chemical structure, RU58841 is derived from a imidazole ring system, which is a common structure in many pharmaceutical compounds. The compound has been noted for its potential in topical applications due to its ability to act locally on androgen receptors in the skin, particularly in the scalp, to reduce hair follicle miniaturization caused by androgens.

Despite showing promise in early research, RU58841 was never commercialized as a pharmaceutical drug. However, it has gained attention in recent years within certain communities exploring experimental treatments for hair loss.c

RU58841, also known as ‌1-(4-fluoronophenyl)-2,5-dimethyl-1H-imidazol-4-carboxylic acid ethyl ester‌ or more fully as ‌ethyl 1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazole-4-carboxylate‌, is a non-steroidal anti-androgen.

It was researched in the 1990s for the potential treatment of androgenetic alopecia (male pattern baldness) and acne. RU58841 acts as a selective androgen receptor modulator by blocking androgen receptors in specific tissues, thereby inhibiting the effects of androgens like dihydrotestosterone (DHT) without significantly affecting systemic hormone levels.

In terms of its chemical structure, RU58841 is derived from a imidazole ring system, which is a common structure in many pharmaceutical compounds. The compound has been noted for its potential in topical applications due to its ability to act locally on androgen receptors in the skin, particularly in the scalp, to reduce hair follicle miniaturization caused by androgens.

Despite showing promise in early research, RU58841 was never commercialized as a pharmaceutical drug. However, it has gained attention in recent years within certain communities exploring experimental treatments for hair loss.